SVCP
ATOS icon

Silicon Valley Capital Partners’s Atossa Therapeutics ATOS Stock Holding History

Silicon Valley Capital Partners’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-258
Closed -$5.89K – 315
2024
Q3 		$5.89K Hold
258
– – ﹤0.01% 274
2024
Q2 		$4.61K Hold
258
– – ﹤0.01% 275
2024
Q1 		$6.97K Buy
+258
New +$4.14K ﹤0.01% 253

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Silicon Valley Capital Partners's ATOS Position: Q4 2024 in Review

Silicon Valley Capital Partners sold out of Atossa Therapeutics (ATOS) in Q4 2024, closing a stake of 258 shares — an estimated $5.89K sold.

Silicon Valley Capital Partners first reported a position in ATOS in Q1 2024 and held it in 3 quarters. The position peaked at $6.97K in Q1 2024. 86 funds tracked by Wall St. Rank hold ATOS as of Q4 2024.

  • Silicon Valley Capital Partners reported no remaining Atossa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Silicon Valley Capital Partners sold 258 Atossa Therapeutics shares in Q4 2024, an estimated $5.89K.
  • Silicon Valley Capital Partners first reported a position in Atossa Therapeutics in Q1 2024 and held it in 3 quarters.
  • Silicon Valley Capital Partners's Atossa Therapeutics position peaked at $6.97K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2024.

Based on Silicon Valley Capital Partners's 13F filing for Q4 2024, filed 29 Jan 2025.